Sunshine Biopharma, Inc. Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound

Published: Apr 09, 2012

MONTREAL--(BUSINESS WIRE)--Sunshine Biopharma Inc. (OTCBB: SBFM) is pleased to announce that it has recently received notification that the United States Patent and Trademark Office has issued a “Notice of Allowance” for the patent application covering its lead anti-tumor compound, Adva-27a. The allowed claims protect Adva-27a and extensively cover various formulations, derivatives and cancer applications. Sunshine Biopharma’s recently announced preclinical results showed that Adva-27a has an excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of cancer cells, particularly multidrug resistant Breast Cancer cells. Adva-27a is appears to be unique in its ability to destroy multidrug resistant cancer cells. Sunshine Biopharma is moving forward with the next steps in the development of Adva-27a which include GMP manufacturing, IND-enabling studies and Phase I clinical trials.

Back to news